Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Amneal Pharmaceuticals Inc (AMRX)

4.98   -0.12 (-2.35%) 02-25 12:13
Open: 5.05 Pre. Close: 5.1
High: 5.14 Low: 4.96
Volume: 357,942 Market Cap: 735M
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It has operations in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.187 - 5.216 5.216 - 5.243
Low: 4.756 - 4.793 4.793 - 4.826
Close: 5.045 - 5.1 5.1 - 5.15

Technical analysis

as of: 2021-02-25 11:41:54 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 6.53     One year: 7.22
Support: Support1: 4.63    Support2: 3.85
Resistance: Resistance1: 5.59    Resistance2: 6.18
Pivot: 5.48
Moving Average: MA(5): 5.18     MA(20): 5.34
MA(100): 4.69     MA(250): 4.32
MACD: MACD(12,26): 0.08     Signal(9): 0.18
Stochastic oscillator: %K(14,3): 16.67     %D(3): 25.39
RSI: RSI(14): 44.59
52-week: High: 6.18  Low: 2.40  Change(%): 29.6
Average Vol(K): 3-Month: 116512  10-Days: 127681

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
AMRX has closed above bottom band by 14.9%. Bollinger Bands are 47.5% wider than normal. The large width of the bands suggest high volatility as compared to AMRX's normal range. The bands have been in this wide range for 11 bars. This is a sign that the current trend might continue.

Headline News

Thu, 25 Feb 2021
Why Amneal Pharmaceuticals (AMRX) Might Surprise This Earnings Season - Nasdaq

Tue, 23 Feb 2021
Amneal Pharmaceuticals Inc (AMRX) is lower byin a Week, Should You Accumulate? - InvestorsObserver

Mon, 22 Feb 2021
Amneal to Virtually Participate at Upcoming Investor Conferences - Business Wire

Thu, 18 Feb 2021
Analysts Anticipate Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Will Post Quarterly Sales of $502.23 Million - MarketBeat

Thu, 11 Feb 2021
Should You Buy Amneal Pharmaceuticals Inc (AMRX) Stock Thursday? - InvestorsObserver

Wed, 10 Feb 2021
SVB Leerink Comments on Amneal Pharmaceuticals, Inc.'s Q1 2021 Earnings (NYSE:AMRX) - MarketBeat

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers General Specialty & Generic
Shares Out. (M) 148
Shares Float (M) 94
% Held by Insiders 10.43
% Held by Institutions 69.86
Shares Short (K) 6,090
Shares Short P. Month (K) 6,530

Stock Financials

EPS 0.418
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 2.040
Profit Margin 3.30
Operating Margin 7.94
Return on Assets (ttm) 2.4
Return on Equity (ttm) 2.8
Qtrly Rev. Growth 37.3
Gross Profit (p.s.) 3.366
Sales Per Share 12.735
EBITDA (p.s.) 2.568
Qtrly Earnings Growth
Operating Cash Flow (M) 222
Levered Free Cash Flow (M) 75

Stock Valuations

PE Ratio 11.94
PEG Ratio
Price to Book value 2.45
Price to Sales 0.39
Price to Cash Flow 3.32

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.